Assessment and proper reporting of adverse events (AEs) and suspected adverse drug reactions (ADRs) form the basis of risk/benefit analysis applied to investigational products. Tracking and assessing different types of AEs and determining which are related to the investigational drug under study are considered some of the most critical roles at research sites.